Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $77.00 price target on the biotechnology company’s stock. CAPR has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and set […]
More Stories
Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) and Plus Therapeutics (NASDAQ:PSTV) Financial Comparison
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN – Get Free Report) are both small-cap...
Massimo Group (NASDAQ:MAMO) Trading Up 4% – What’s Next?
Shares of Massimo Group (NASDAQ:MAMO – Get Free Report) were up 4% on Wednesday . The company traded as high...
AlTi Global (NASDAQ:ALTI) Share Price Crosses Above 200-Day Moving Average – What’s Next?
AlTi Global, Inc. (NASDAQ:ALTI – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday...
AVEVA Group (LON:AVV) Shares Cross Above 200-Day Moving Average – Here’s What Happened
AVEVA Group plc (LON:AVV – Get Free Report)’s share price crossed above its two hundred day moving average during trading...
Culp (NYSE:CULP) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?
Culp, Inc. (NYSE:CULP – Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The...
THG Plc (OTCMKTS:THGPF) Short Interest Update
THG Plc (OTCMKTS:THGPF – Get Free Report) was the target of a significant increase in short interest in October. As...